Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04569175
Other study ID # CHUBX 2020/25
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 6, 2020
Est. completion date April 5, 2022

Study information

Verified date July 2022
Source University Hospital, Bordeaux
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study includes 30 patients with Meniere's disease confirmed with AAO-HNS criteria. The aim of this study is to compare the new optimized 3D FLAIR sequence developed at our site with a standard 3D FLAIR sequence performed 4h after a single intravenous dose of macrocyclic gadolinium-based contrast agents for the detection of endolymphatic hydrops. The patients will be explored with the new 3D FLAIR optimized sequence before injection (method to validate) and again 4 hours after contrast media administration with the same sequence 3D FLAIR


Description:

Meniere's disease (MD) is a pathology of the inner ear defined by episodes of spontaneous vertigo usually accompanied by tinnitus, pressure within the ear and fluctuating sensorineural hearing loss. Endolymphatic hydrops (EH) is the main pathophysiological substratum of Meniere's disease. Temporal bone MRI has long been used performed to exclude other pathologies mimicking MD, such as vestibular schwannoma or endolymphatic sac tumor. Currently, delayed 3D-FLAIR sequence is the imaging technique of choice for the diagnosis of endolymphatic hydrops. The endolymphatic space could be assessed on MRI with 3D-FLAIR sequences delayed acquisition after the intravenous administration of gadolinium. The saccule appears to be the most involved structure in MD. The reproducibility of the hydrops protocols with various MRI scan manufacturers is debatable. Because endo and peri lymphatic spaces have different biochemical compositions, a new FLAIR 3D sequence on healthy volunteers can be tuned in order to separate endo and peri lymphatic spaces. The hypothesis of the study is that this new method could detect saccular hydrops with the same performances as the standard FLAIR that is done after gadolinium injection. This study will prospectively include 30 patients with MD confirmed with AAO-HNS criteria . All patients will sign an informed consent. They will be explored with the new 3D FLAIR optimized sequence without injection (method to validate). Then, they will be injected, and they will be explored again 4 hours after contrast product administration with the same sequence (the reference method),to take advantage of the intravenous injection of gadolinium that will be performed in the care. The optimized non enhanced 3D FLAIR sequence will be compared with the reference method and with the same sequence four hours after gadolinium injection.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date April 5, 2022
Est. primary completion date April 5, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Man or woman - older than 18 years old. - Uni- or bilateral definite or probable clinical diagnosis of MD based on the AAO-HNS guidelines revised in 2015. - Patient eligible for having contrast-enhanced MRI. - Patient affiliated of beneficiary of health insurance - Patient has signed the Informed consent form. Non inclusion criteria: - History of other pathology of the inner ear. - History of surgery on the middle or inner ear (tympanoplasty, endolymphatic sac drainage, vestibular schwannoma). - Pregnant (contraceptive method, HAS criteria) or nursing mothers - Contraindications to performing MRI (pace maker, metallic shards, claustrophobia) - Contraindications (relative) to injecting gadolinium (severe renal failure due to the risk of systemic nephrogenic fibrosis, history of allergic reaction) - Patient under legal protection

Study Design


Related Conditions & MeSH terms


Intervention

Other:
3D Flair sequence
Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product). All patients will have the same intervention as each patient is its own control

Locations

Country Name City State
France CHU Bordeaux Bordeaux

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other Meniere disease categorization Patient's clinical categorization according to the diagnostic criteria for Meniere's disease formulated by the Classification Committee of the Barany Society in 2015 : definite Meniere's disease and probable Meniere's disease. 1 hour before baseline, baseline, 4 hours after baseline
Other Degree of endolymphatic hydrops degree of endolymphatic hydrops: grade I/II/III 1 hour before baseline, baseline, 4 hours after baseline
Other Volume of endolymphatic hydrops Volume of endolymphatic hydrops: quantification (mm3) 1 hour before baseline, baseline, 4 hours after baseline
Other Peak width peak width in multifrequency tympanometry: average +/- standard deviation 1 hour before baseline, baseline, 4 hours after baseline
Other Resonant frequency Resonant frequency: 0 to 2000 Hz 1 hour before baseline, baseline, 4 hours after baseline
Primary Kappa coeficient the non-inferiority of the non-enhanced Flair sequence compared to the reference technique by indirect comparison with the reference method (Kappa coefficient > or equal to 0.81). 1 hour before baseline (usual care MRI)
Secondary inter-observer correlation inter-observer correlation coefficient (weighted Kappa). 1 hour before baseline, baseline, 4 hours after baseline
See also
  Status Clinical Trial Phase
Recruiting NCT04835688 - Ventilation Tube Insertion for Unilateral Menière's Disease N/A
Recruiting NCT05851508 - The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere's Disease Phase 3
Not yet recruiting NCT05322538 - Menier's Disease - Bone Density Study N/A
Completed NCT05328895 - Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease N/A
Not yet recruiting NCT05582148 - Meniere Disease and Hearing Aids N/A
Completed NCT05844657 - Comprehensive Evaluation in Patients With Meniere's Disease
Completed NCT04902963 - What is the Tympanic Membrane Healing Time After Insertion of a Gelfoam PE Tube? N/A
Completed NCT04686695 - Transcutaneous Auricular Vagus Nerve Stimulation Treatment on Meniere Disease N/A
Recruiting NCT04815187 - Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease Phase 4
Recruiting NCT06278129 - Evaluation of the Diagnostic and Prognostic Efficacy of MRI in Acute Sensorineural Hearing Loss and Ménière's Disease
Recruiting NCT04766853 - Verification of the Efficacy/Safety of the Intratympanic Drug Delivery for Hearing Loss Phase 1/Phase 2
Recruiting NCT04370366 - Imaging of Endolymphatic Hydrops at 7T MRI
Enrolling by invitation NCT03520322 - A Study of a Mastoid Device in Subjects With Ménière's Disease N/A
Withdrawn NCT04674735 - Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere's Disease Phase 1
Not yet recruiting NCT05424302 - Effect of Peripheral Vestibular Disease Location on Outcomes Following Home-based Virtual Reality Vestibular Therapy N/A
Recruiting NCT03795675 - CI Following VS Removal or Labyrinthectomy N/A
Completed NCT04218123 - Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes Phase 2/Phase 3
Withdrawn NCT02371798 - Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis? N/A
Completed NCT05960786 - Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand N/A
Terminated NCT02529475 - Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS) Phase 4